Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase I study of tyrosine kinase 2 inhibitor ICP-332 begins in China

Aug. 16, 2021

Lomecel-B improves physical function in phase IIb study in patients with aging frailty

Aug. 16, 2021

Primary endpoint not met in phase II trial of trimodulin in patients with severe COVID-19

Aug. 16, 2021

Apeximmune Therapeutics describes anti-B7-H4 constructs for cancer

Aug. 16, 2021

Beijing Jacobio Pharmaceuticals presents new AURK1 inhibitors

Aug. 16, 2021

Kangpu Biopharmaceuticals divulges CRBN-binding isoindolines

Aug. 16, 2021

MedImmune patents new ADCs for cancer

Aug. 16, 2021

TYK2 inhibitor NDI-034858 enters phase II investigation for plaque psoriasis

Aug. 16, 2021

Trial starts enrollment to assess LY-3361237 in patients with psoriasis

Aug. 16, 2021

Phase I trial begins for DVX-201 allogeneic NK cells in COVID-19 patients

Aug. 16, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...